The approval marks another milestone in the company’s efforts to expand patient access to affordable biologic therapies in Canada. The newly approved autoinjector complements Health Canada’s earlier approval granted in October 2025 for Yesintek® prefilled syringes, vials, and intravenous formulation. With the addition of the autoinjector presentation, Biocon aims to provide patients and healthcare professionals with greater flexibility in treatment administration. According to the company, the Yesintek® Autoinjector offers a patient-friendly administration option that is not currently available with the originator product in Canada. The device is expected to support more customized treatment approaches across different healthcare settings while addressing varying patient needs.